APDS
Clinical trials for APDS explained in plain language.
Never miss a new study
Get alerted when new APDS trials appear
Sign up with your email to follow new studies for APDS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare immune disease: drug targets root cause
Disease control OngoingThis study tests a drug called leniolisib in children aged 4 to 11 with APDS, a rare genetic condition that causes a faulty immune system. The goal is to see if the drug is safe and can control the disease by blocking an overactive immune signal. About 15 children will take the d…
Matched conditions: APDS
Phase: PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
Promising drug targets rare immune disorder in toddlers
Disease control OngoingThis study tests a drug called leniolisib in children aged 1 to 6 years who have a rare genetic immune disease called APDS. The goal is to see if the drug is safe and can help control the disease by reducing swollen lymph nodes and other symptoms. About 16 children will take the …
Matched conditions: APDS
Phase: PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC